The AJMC® Comprehensive Genomic Profiling compendium is a comprehensive resource for clinical news and expert insights for the next-generation sequencing approach to assess genes for the purpose of therapy guidance.
AACR Posters Demonstrate CGP for Biomarker Detection and Multiomics Profiling
June 11th 2022Posters from the American Association of Cancer Research (AACR) Annual Meeting demonstrated the use of genomic profiling and sequencing can detect immunotherapy biomarkers and predict clinical outcomes in patients with cancer.
Read More
Contributor: The Case for Education and Clinical Decision Support With Pharmacogenetics
June 2nd 2022Prescribing is a complex process with multiple factors to consider on top of the 3 primary questions about effectiveness, harm, and cost. Pharmacogenetics has put this complexity under the spotlight and prompted educational programs and the development of new clinical decision support systems.
Read More
Contributor: The Convergence of Value-Based Care and Lab Testing Growth
May 17th 2022Today, health plans are shifting dollars to more value-based contracts along with investments in population health management. Digitizing lab results across all care settings and unlocking the potential of lab values can help health plans reach the Triple Aim of improving the patient experience, improving the health of populations, and reducing the per-member cost of health care.
Read More
Contributor: Top 3 Future Therapies to Drive Hemophilia Treatment Market Growth
April 24th 2022The trends in the hemophilia treatment market are gaining momentum with increasing incidences of hemophilia A and B and staggering need for their treatments, including gene, anti-tissue factor pathway inhibitor, and factor replacement therapies.
Read More
NPC's Michael Ciarametaro on How Clinics Can Surmount Gene Therapy Data Collection Barriers
April 22nd 2022Michael Ciarametaro, MBA, vice president of research at the National Pharmaceutical Council, highlights steps clinics can take to mitigate issues related to data collection regarding cell and gene therapies.
Watch
Spotlighting Health-, Cost-Related Benefits of Genomic Testing and How Employers Can Drive Adoption
April 20th 2022Key opinion leaders addressed cost, accessibility, and other barriers limiting use of comprehensive genomic profiling (CGP), and how employers can help drive preventive care and precision medicine through CGP.
Read More
Expert: Better Harmony Is Needed to Prevent Compromised Specimens During CGP Testing
April 15th 2022Despite technological advancements, there are still many factors that can cause specimens for comprehensive genomic profiling (CGP) testing to become compromised, potentially leading to inaccurate prognostic results, according to a recent webinar.
Read More
Genomic Profiling Utility for Targeted Therapy Selection Shown in Advanced GI Cancers
April 8th 2022The clinical utility of genomic profiling was demonstrated in patients with advanced gastrointestinal (GI) cancers whose access to targeted therapies based on tissue-based assay findings was similar to those with non-GI cancers.
Read More
Dr Jorge Plutzky: New Advances in Science, Medicine Need to Move Into Practice Quicker
April 6th 2022The acceleration of science and medicine is exciting, but these new advances are not always moving into practice, said Jorge Plutzky, MD, director of the Vascular Disease Prevention Program and director of Preventive Cardiology at Brigham and Women’s Hospital, and associate professor of medicine at Harvard Medical School.
Watch
Dr Edmondo Robinson Highlights the Importance of a Complete Patient View When Delivering Care
March 30th 2022Everything from the genomic data for the cancer to the zip code of a patient matters when delivery care, said Edmondo Robinson, MD, MBA, MS, FACP, senior vice president and chief digital officer at Moffitt Cancer Center.
Watch
ASCO GU 2022: Comparing Tumor Genomic Landscape Across Age, Disease Demographics
March 28th 2022Posters from the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) 2022 look at how the tumor genomic landscape differs based on age and type of urothelial carcinoma.
Read More
FDA Approves FoundationOne CDx to Identify EGFR Therapeutics for Certain Patients With NSCLC
March 19th 2022FoundationOne CDx has been approved as a companion diagnostic to identify patients with non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 alternations eligible for treatment with EGFR tyrosine kinase inhibitors.
Read More
Mount Sinai Researchers Discuss Milestones in Understanding Genetic Variants
March 14th 2022Ron Do, PhD, associate professor, Charles Bronfman Institute for Personalized Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, discuss their hopes for their findings and how genetic data are being used in health care.
Watch
Mount Sinai Researchers Explain Implications of Genetic Testing for Providers
March 12th 2022Ron Do, PhD, associate professor, Charles Bronfman Institute for Personalized Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, explain their study's implications for providers and how age plays a role in genetic variant penetrance.
Watch
Mount Sinai Researchers Explain Biobanks Used in Clinical Variants Study
March 4th 2022Ron Do, PhD, associate professor, Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, explain the differences between the biobanks used in their study on population-based penetrance of clinical variants.
Watch
Mount Sinai Researchers Discuss Findings on Risk of Pathogenic, Loss-of-Function Clinical Variants
February 26th 2022Ron Do, PhD, associate professor, Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, discuss the results of their recent study measuring population-based penetrance of pathogenic and loss-of-function clinical variants.
Watch
How Employers Can Achieve High-Value, Cost-Effective Oncology Care Through Genomic Profiling
February 26th 2022A webinar by the National Cancer Treatment Alliance discussed current use and diagnostic/therapeutic benefits of comprehensive genomic profiling in oncology, as well as recommendations for employers and benefit consultants considering biomarker testing.
Read More
Mount Sinai Researchers on Importance of Understanding Genetic Variants and Disease Risk
February 19th 2022Ron Do, PhD, associate professor of the Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, explain the importance of their recent study measuring population-based penetrance of pathogenic and loss-of-function clinical variants.
Watch
FDA Grants Breakthrough Device Designation to Foundation Medicine’s ctDNA Tracker
February 15th 2022Foundation Medicine’s circulating tumor DNA (ctDNA) detection and monitoring assay, FoundationOne Tracker, was granted a Breakthrough Device Designation from the FDA, streamlining the approval and review processes to give patients and providers earlier access to the device.
Read More